Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:26:19.430Z.
Calculation as of: 2026-10-06T13:26:19.430Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5259cb07e2fbb96f0e8f0a81153900e7454c243d03e5865b91db876a0b9f3ffb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$417.82M
EV/EBITDA Ratio
N/A
TTM Avg
10.71x
3Y Avg
10.71x
5Y Avg
10.71x
Market Cap
$412.94M
EV/EBITDA Ratio
N/A
TTM Avg
5.73x
3Y Avg
28.73x
5Y Avg
28.73x
Market Cap
$445.71M
EV/EBITDA Ratio
0.44x
TTM Avg
1.11x
3Y Avg
1.11x
5Y Avg
1.11x
Market Cap
$408.21M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$452.63M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$453.70M
EV/EBITDA Ratio
N/A
TTM Avg
81.39x
3Y Avg
32.05x
5Y Avg
24.98x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $428.16M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $417.82M | N/A | 10.71x | 10.71x | 10.71x |
| Carlsmed, Inc. (CARL)vs › | $419.46M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.94M | N/A | 5.73x | 28.73x | 28.73x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 0.44x | 1.11x | 1.11x | 1.11x |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $452.63M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | 81.39x | 32.05x | 24.98x |
| Kamada Ltd. (KMDA)vs › | $461.55M | 10.29x | 9.91x | 9.78x | 16.95x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
